Aggrenox Extended-Release Dipyridamole Claim Must Be Substantiated - FDA
Executive Summary
Boehringer Ingelheim must show that the dipyridamole component of Aggrenox is different from immediate-release dipyridamole to substantiate its extended-release claim, FDA said in its Nov. 22 approval letter for the dipyridamole/aspirin stroke prevention treatment.